Navigation path

Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Equilis West Nile   
Auth. number : EU/2/13/151
Active substance : Inactivated chimeric flavivirus strain YF-WN
ATC: Anatomical main group: QI - Immunologicals
Therapeutic subgroup: QI05 - Immunologicals for equidae
Pharmacological subgroup: QI05A - Horse
Chemical subgroup: QI05AA - Inactivated viral vaccines
Chemical substance: QI05AA10 - west Nile virus
(See WHO ATCvet Index)
Indication: Active immunisation of horses against West Nile virus (WNV) to reduce clinical signs of disease and lesions in the brain and to reduce viraemia.
Onset of immunity: 2 weeks after primary vaccination course of two injections.
Duration of immunity: 12 months.
Marketing Authorisation Holder: Intervet International B.V.
Wim de Körverstraat 35, 5831 AN Boxmeer, Nederland
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
10/06/2013 Centralised - Authorisation EMEA/V/C/2241 (2013)3515 of 06/06/2013